Aelis Farma S.A.S. (69O)
Market Closed
7 Aug, 20:00
XSTU 
€
0. 99
-0.02
-2.0875%
€
- Market Cap
- P/E Ratio
- Div Yield
280 Volume
0 Eps
€ 1.01
Previous Close Want to track 69O and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
69O closed Friday lower at €0.99, a decrease of -2.0875% from Thursday's close, completing a monthly increase of 3.903% or €0.04. Over the past 12 months, 69O stock lost -10.4545%.
69O is not paying dividends to its shareholders.
The last earnings report, released on Mar 31, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
69O Chart
Aelis Farma S.A.S. (69O) FAQ
What is the stock price today?
The current price is €0.99.
On which exchange is it traded?
Aelis Farma S.A.S. is listed on XSTU.
What is its stock symbol?
The ticker symbol is 69O.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Aelis Farma S.A.S. ever had a stock split?
No, there has never been a stock split.
Aelis Farma S.A.S. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Pier Vincenzo Piazza M.D., Ph.D. CEO | XSTU Exchange | FR0014007ZB4 ISIN |
| FR Country | 26 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aelis Farma SA stands out as an innovative biotechnology firm, rooted in the vibrant city of Bordeaux, France, specializing in the advancement of therapeutic solutions targeted at a spectrum of brain diseases. Since its inception in 2013, the company has dedicated itself to pioneering research and development, with a particular focus on crafting signaling-specific inhibitors targeted at CB1 receptors. This niche focus places Aelis Farma at the forefront of addressing some of the most pressing challenges in neuropharmacology and mental health treatment today.
Products and Services
- AEF0117: Currently in the advanced stages of Phase 2b clinical trials, AEF0117 is a groundbreaking drug candidate, distinctively designed to mitigate the adverse effects associated with excessive cannabis consumption. This therapeutic endeavor represents Aelis Farma's commitment to addressing emerging public health concerns, particularly those related to the increasing prevalence of cannabis use disorders.
- AEF0217: Having successfully completed Phase 1 clinical trials, AEF0217 emerges as a promising drug candidate aiming to alleviate cognitive deficits, notably those observed in individuals with Down syndrome. Moreover, AEF0217 harbors the potential to be applied more broadly in the treatment of various cognitive impairments, marking a significant advancement in enhancing the quality of life for individuals faced with such challenges.
Contact Information
Address: 146 rue Lafaurie de Monbadon, Bordeaux, France, 33 000
Phone: 33 5 54 54 23 27
Website: https://www.aelisfarma.com
